Antibody responses to COVID‐19 vaccines in older adults. Issue 4 (27th December 2021)

• Record Type: Journal Article
• Authors: Bag Soytas, Rabia; Cengiz, Mahir; Islamoglu, Mehmet S.; Borku Uysal, Betul; Yavuzer, Serap; Yavuzer, Hakan
• Other Names: Luo Guangxiang (George) guestEditor.; Ly Hinh guestEditor.; Gao Shou‐Jiang guestEditor.
• Is Part Of: Journal of medical virology. Volume 94:Issue 4(2022)
• Page Start: 1650
• Page End: 1654
• Publication Date: 2021-12-27
• Subjects: antibody -- chemiluminescent microparticle immunoassay -- COVID‐19 vaccine -- immunofluorescence assay -- older adults; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.27531
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: Because of the senescence of the immune system, antibody response to the COVID‐19 vaccines may differ from older to younger adults. The study aim compares the titers of SARS‐CoV‐2 IgG antibody of patients ≥60 years who received three doses of CoronaVac vaccine and those who received two doses of CoronaVac+1 dose of Pfizer‐BioNTech after 1 month of the last vaccination. Patients ≥60 years who received the CoronaVac vaccine between March 1, 2021, and April 30, 2021, who did not have COVID‐19 disease before the first dose of vaccination and were negative for COVID‐19 antibodies, whose antibodies were tested before the third dose of vaccination, and who did not have any COVID‐19 disease during the follow‐up were included. The demographic characteristics and comorbidities of patients were recorded. An immunofluorescence assay (IFA) fast test and a chemiluminescent microparticle immunoassay (Abbott) were used to measure SARS‐CoV‐2 quantitative antibody levels at the first month after the third‐dose vaccine. Totally 81 patients, 41 patients in third dose of the CoronaVac group (female:male 18:23, mean age 69.4 ± 8.5), and 40 patients in third dose of the Pfizer‐BioNTech group (female:male 15:25, mean age 69.9 ± 9.1) were included. The patients' comorbidities in the groups were similar. The titers of IgG antibodies to SARS‐CoV‐2 measured according to both IFA and Abbott Kit at first month the third dose vaccination was significantly higher in the Pfizer‐BioNTech group ( p ≥ 0.001, p = 0.012, respectively). The results report that the formed immunity in the first month after the two doses of CoronaVac+1 dose Pfizer‐BioNTech vaccine was higher than three doses of CoronaVac vaccine in older adults. Highlights: The antibody response to the COVID‐19 vaccines may differ from older to younger adults. Knowing the level of antibodies to vaccines in older adults is important in guiding vaccine selection. The formed immunity in the first month after the two doses CoronaVac+one dose Pfizer‐BioNTech vaccine was higher than three doses CoronaVac vaccine in older adults.